Perampanel Monotherapy for Focal and Generalized Epilepsy in Clinical Practice

Table 2

Summary of safety and tolerability (tolerability population).

Total PWE
PWE with any AE, (%)	89 (45.2)
Most frequently reported AEs^†, (%)
Dizziness/vertigo	33 (16.8)
Irritability	22 (11.2)
Somnolence	18 (9.1)
Depression	13 (6.6)
PWE with AEs leading to discontinuation (12 months), (%)	18 (13.7)^‡
Types of AEs leading to discontinuation (12 months), (%)
Depression	10 (7.6)^‡
Dizziness/vertigo	8 (6.1)^‡
Irritability	8 (6.1)^‡
Somnolence	5 (3.8)^‡
Instability/ataxia	4 (3.1)^‡
Confusion	1 (0.8)^‡
Dry mouth	1 (0.8)^‡
PWE with any psychiatric AE, (%)	41 (20.8)
PWE with psychiatric AEs who discontinued^§, (%)	17 (10.2)^¶
Types of psychiatric AEs in PWE who discontinued^§, (%)
Depression	10 (6.0)^¶
Irritability	8 (4.8)^¶

^†≥5% of PWE; ^‡; ^§these PWE had psychiatric AEs, but it was not possible to determine if it was these AEs that led to discontinuation; ^¶; AE: adverse event; PWE: people with epilepsy.